Title |
Role of PD-1 in HIV Pathogenesis and as Target for Therapy
|
---|---|
Published in |
Current HIV/AIDS Reports, December 2011
|
DOI | 10.1007/s11904-011-0106-4 |
Pubmed ID | |
Authors |
Filippos Porichis, Daniel E. Kaufmann |
Abstract |
Major advances in Antiretroviral Therapy (ART) have resulted in a dramatic decline in HIV-related deaths. However, no current treatment regimen leads to viral eradication or restoration of HIV-specific immune responses capable of durable viral control after cessation of ART. Thus, there is a need for novel interventions that could complement ART in order to eliminate virus or reach a state of "functional cure." It has been shown in murine models and humans that the negative co-signaling molecule programmed-death 1 (PD-1) plays an active and reversible role in mediating T-cell exhaustion in chronic infections. This review summarizes recent advances in our understanding of the PD-1 pathway in HIV infection, and the lessons learned from studies in the SIV model and cancer. We discuss the potential of immunotherapeutic interventions targeting PD-1 in order to augment immune responses or facilitate viral eradication. We also present the challenges to therapies targeting immunoregulatory networks. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 1% |
Japan | 1 | <1% |
Denmark | 1 | <1% |
Unknown | 133 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 29 | 21% |
Student > Ph. D. Student | 20 | 15% |
Student > Master | 18 | 13% |
Student > Bachelor | 17 | 12% |
Student > Doctoral Student | 9 | 7% |
Other | 25 | 18% |
Unknown | 19 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 35 | 26% |
Medicine and Dentistry | 28 | 20% |
Immunology and Microbiology | 20 | 15% |
Biochemistry, Genetics and Molecular Biology | 16 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 4% |
Other | 9 | 7% |
Unknown | 23 | 17% |